ARROWHEAD PHARMACEUTICALS, INC. Preferred Stock, Value, Issued
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Preferred Stock, Value, Issued of $16 as of 2016-09-30, per its 10-K filed 2017-12-12.
Discontinued › Balance Sheet › Equity, Attributable to Parent
us-gaap:PreferredStockValue · last filed 2017-12-12
- 2016-09-30: Preferred Stock, Value, Issued $16.00.
- 2016-06-30: Preferred Stock, Value, Issued $16.00.
- 2016-03-31: Preferred Stock, Value, Issued $16.00.
- 2015-12-31: Preferred Stock, Value, Issued $16.00.
| Period end | Preferred Stock, Value, Issued |
|---|---|
| 2016-09-30 | $16.00 10-K · filed 2017-12-12 |
| 2016-06-30 | $16.00 10-Q · filed 2016-08-09 |
| 2016-03-31 | $16.00 10-Q · filed 2016-05-10 |
| 2015-12-31 | $16.00 10-Q · filed 2016-02-09 |
| 2015-09-30 | $16.00 10-K · filed 2016-12-14 |
| 2015-06-30 | $16.00 10-Q · filed 2015-08-04 |
| 2015-03-31 | $16.00 10-Q · filed 2015-05-11 |
| 2014-12-31 | $18.00 10-Q · filed 2015-02-09 |
| 2014-09-30 | $18.00 10-K · filed 2015-12-14 |
| 2014-06-30 | $21.00 10-Q · filed 2014-08-12 |
| 2014-03-31 | $21.00 10-Q · filed 2014-05-06 |
| 2013-12-31 | $51.00 10-Q · filed 2014-02-04 |
| 2013-09-30 | $10.00 10-K · filed 2014-11-25 |
| 2013-06-30 | $10.00 10-Q · filed 2013-08-07 |
| 2011-12-31 | $1.00 10-Q · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |